Advances in the research of pharmacogenomics of cyclophosphamide / 药学学报
Acta Pharmaceutica Sinica
; (12): 971-976, 2014.
Artigo
em Chinês
| WPRIM (Pacífico Ocidental)
| ID: wpr-299181
Biblioteca responsável:
WPRO
ABSTRACT
Cyclophosphamide (CPA) is the most common alkylating antineoplastic agent, as well as a strong immunosuppressant that is frequently applied to autoimmune diseases and organ transplantation. It is metabolized by cytochrome P450 oxidases (CYPs) to its active metabolite which played a critical role in therapy. CPA has serious and even fatal side effects, and its efficacy and adverse reactions are significantly varied among individuals. In this review, the association of the genetic polymorphisms in the metabolic enzymes and transporters involved in the disposition of CPA with the efficacy and adverse effects of CPA were summarized, thereby providing fundamental reference for further pharmacogenomic study of CPA.
Texto completo:
Disponível
Base de dados:
WPRIM (Pacífico Ocidental)
Assunto principal:
Farmacogenética
/
Farmacologia
/
NADPH-Ferri-Hemoproteína Redutase
/
Antineoplásicos Alquilantes
/
Ciclofosfamida
/
Metabolismo
Limite:
Humanos
Idioma:
Chinês
Revista:
Acta Pharmaceutica Sinica
Ano de publicação:
2014
Tipo de documento:
Artigo